Volha Barysevich/iStock by way of Getty Photographs
Passage Bio (NASDAQ:PASG) shares had been up 9% Wednesday after the biotech firm reported encouraging Part 1/2 knowledge for its gene remedy candidate PBFT02 within the remedy of a kind of early onset dementia and issued an replace on its drug packages.
The biotech firm mentioned knowledge from its upliFT-D research of PBFT02 within the remedy of frontotemporal dementia with granulin mutations, or FTD-GRN, exceeded its expectations. Consequently, it intends to not solely proceed growing the remedy for FTD-GRN but in addition discover its potential in treating neurodegenerative ailments similar to FTD-c90rf72, ALS and Alzheimer’s.
Passage additionally mentioned that it’s “actively exploring” partnerships to advance its GM1 gangliosidosis and medical stage pediatric packages. It’s also prioritizing its Huntington’s illness preclinical program via its partnership with the Penn Gene Remedy Program.
The corporate expects to provoke dosing for Cohort 2 FTD-GRN sufferers within the first half of 2024 and report six-month knowledge from Cohort 1 sufferers within the second half of the 12 months.